Company news
Xeris Biopharma Holdings, Inc. news in 2019
Xeris Biopharma Holdings, Inc.'s news releases, calls and decks from 2019, newest first.
Xeris Pharmaceuticals Announces Positive Topline Results From the In-clinic Stage of the Phase 2 Study of Its Developmental Ready-to-use (RTU) Glucagon in Patients at Risk of Postprandial Hypoglycemia Following Bariatric Surgery
December 9, 2019
Xeris Pharmaceuticals Provides a Business Update During Recent Investor Conference
November 20, 2019
Xeris Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights
November 6, 2019
Xeris Pharmaceuticals Appoints Mark Thierer to Board of Directors
September 30, 2019
Xeris Pharmaceuticals Begins Dosing Patients in a Phase 2 Clinical Trial Evaluating Its Novel Fixed-Ratio Co-Formulation of Pramlintide-Insulin for Diabetes
September 18, 2019
Xeris Pharmaceuticals Announces Expanded $85 Million Debt Facility With Oxford Finance and Silicon Valley Bank
September 9, 2019
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 29, 2019